Clinical Trials
Saturday, January 26th, 2013
STROKEAHA: January 3, 2013 Background and Purpose—The so-called smoking-thrombolysis paradox of an improved outcome after thrombolysis was first described in smokers with myocardial infarction. We investigated whether reperfusion rates and clinical outcome differ between smokers and nonsmokers with ischemic stroke after intravenous tissue plasminogen activator. Methods—Consecutive acute ischemic stroke patients, who had magnetic resonance imaging before […]
Clinical Trials
Saturday, January 26th, 2013
STROKEAHA: November 27, 2012 Background and Purpose—Observational studies indicate that outpatient cardiac monitoring detects previously undiagnosed atrial fibrillation (AF) in 5% to 20% of patients with recent stroke. However, it remains unknown whether the yield of monitoring exceeds that of routine clinical follow-up. Methods—In a pilot trial, we randomly assigned 40 patients with cryptogenic ischemic stroke […]
Clinical Trials
Thursday, January 17th, 2013
CIRCULATIONAHA: January 16, 2013 Background—The multicenter PROTECT AF study was conducted to determine whether percutaneous left atrial appendage (LAA) closure with a filter device (Watchman) was noninferior to warfarin for stroke prevention in atrial fibrillation (AF). Methods and Results—Patients (n = 707) with nonvalvular AF and at least one risk factor (age > 75, hypertension, heart […]
Clinical Trials
Thursday, January 17th, 2013
Theincidentaleconomist: January 16, 2013 The British Medical Journal posted on their website, Clinical Evidence, the results of an analysis of randomized controlled trials focusing on harms and benefits of 3,000 medical treatments. The effectiveness of each treatment was rated based on six criteria: (a) beneficial, (b) likely to be beneficial, (c) trade-off between benefits and harms, (d) unlikely to […]
Clinical Trials
Thursday, January 17th, 2013
American College of Cardiology Foundation: January 14, 2013 Atrial fibrillation (AF) is the most common sustained arrhythmia1 and catheter ablation aiming to eliminate tissue critical to AF2 is found to be more effective than medications for its treatment.3-5 Nevertheless, many patients require multiple, lengthy, and costly ablation procedures that confer at least modest risk.2 AF ablation success is likely limited […]
Clinical Trials
Thursday, January 17th, 2013
STROKEAHA: January 10, 2013 Background and Purpose—Strokes have especially devastating implications if they occur early in life; however, only limited information exists on the characteristics of acute cerebrovascular disease in young adults. Although risk factors and manifestation of atherosclerosis are commonly associated with stroke in the elderly, recent data suggests different causes for stroke in the […]
Clinical Trials
Thursday, January 17th, 2013
STROKEAHA: January 10, 2013 Background and Purpose—Strokes have especially devastating implications if they occur early in life; however, only limited information exists on the characteristics of acute cerebrovascular disease in young adults. Although risk factors and manifestation of atherosclerosis are commonly associated with stroke in the elderly, recent data suggests different causes for stroke in the […]
Clinical Trials
Thursday, January 17th, 2013
STROKEAHA: January 10, 2013 ackground and Purpose—Although aspirin is effective in prevention of stroke, fewer studies have examined the impact of aspirin on stroke morbidity. Methods—The Women’s Health Study is a completed randomized, placebo-controlled trial designed to test the effect of low-dose aspirin and vitamin E in the primary prevention of cardiovascular disease and cancer, which […]
Clinical Trials
Sunday, January 13th, 2013
Jnis.bmj: January 3, 2013 Background The magnitude of treatment effect in acute stroke depends on several factors, including time from symptom onset (TFSO) to treatment and severity of the initial insult. Objective To report further evaluation of NeuroFlo therapy, focusing on the effect of time and stroke severity. Methods SENTIS was a prospective randomized trial (N=515) comparing standard medical […]
Clinical Trials
Sunday, January 13th, 2013
CIRCULATIONAHA: December 27, 2012 Background—RE-LY showed that dabigatran etexilate 150 mg bid (DE150) was superior, and 110 mg bid (DE110) non-inferior to warfarin in preventing stroke and systemic embolism (SSE) in patients with atrial fibrillation (AF). In this subgroup analysis, we assess the efficacy and safety of dabigatran in patients who did and didn’t receive concomitant […]
